预约演示
更新于：2026-05-24
Perindopril Arginine
精氨酸培哚普利
更新于：2026-05-24
概要
基本信息
原研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H46N6O7 |
InChIKeyRYCSJJXKEWBUTI-YDYAIEMNSA-N |
CAS号612548-45-5 |
关联
10
项与 精氨酸培哚普利 相关的临床试验CTR20240279
精氨酸培哚普利片在中国成年健康受试者中的生物等效性研究
CTR20233406
精氨酸培哚普利片人体生物等效性研究
CTR20230504
一项单中心、随机、开放、单次给药、两制剂、两周期交叉设计研究评价杭州仟源保灵药业有限公司的精氨酸培哚普利片与Les Laboratoires Servier的精氨酸培哚普利片在健康受试者中的空腹和餐后状态下的生物等效性研究
100 项与 精氨酸培哚普利 相关的临床结果
登录后查看更多信息
100 项与 精氨酸培哚普利 相关的转化医学
登录后查看更多信息
100 项与 精氨酸培哚普利 相关的专利（医药）
登录后查看更多信息
1,897
项与 精氨酸培哚普利 相关的文献（医药）2026-06-01Journal of the American Medical Directors Association
Impact of Different Antihypertensive Drug Classes on Incident Dementia in Older Adults: A Systematic Review and Meta-Analysis
Review
作者: Zhu, Xiaojie ; Ding, Lu ; Wu, Huihong ; Zhang, Yuanxi ; Wang, Xiangzhao ; Liu, Ziwang ; Zhang, Meng ; Chen, Zixin
OBJECTIVES:
To evaluate the association between different classes of antihypertensive medications (AHMs) and dementia risk in older adults through systematic review and meta-analysis.
DESIGN:
Systematic review and exploratory network meta-analysis (NMA) following PRISMA-MOOSE guidelines. For traditional meta-analysis, random-effects models (DerSimonian-Laird method) were used for dichotomous outcomes, and fixed-effects models for continuous outcomes. Exploratory NMA employed a frequentist fixed-effects model (Stata 18 network package), as the sparse network precluded Bayesian estimation.
SETTING AND PARTICIPANTS:
Four multicenter randomized controlled trials [Syst-Eur, Perindopril Protection Against Recurrent Stroke Study (PROGRESS), SCOPE, HYVET-COG] comprising 16,823 hypertensive older adults without dementia at baseline, with follow-up durations of 2.0-3.9 years.
METHODS:
Literature searches were conducted in PubMed, Cochrane Library, Web of Science, and Embase from inception to December 31, 2025. Risk of bias was assessed using Cochrane RoB 2, and evidence certainty was evaluated using GRADE. Random-effects models pooled dichotomous outcomes [odds ratios (OR)] and fixed-effects models analyzed continuous outcomes [standardized mean differences (SMDs)].
RESULTS:
Antihypertensive treatment significantly improved cognitive function scores (SMD, 0.06; 95% CI, 0.03-0.09; P < .001, GRADE moderate certainty) and showed a nonsignificant trend toward reduced dementia incidence (OR, 0.89; 95% CI, 0.76-1.05; P = .172, GRADE low certainty). Exploratory NMA suggested calcium channel blockers ranked highest for dementia prevention [surface under the cumulative ranking curve (SUCRA) = 94.7%], while diuretic ± angiotensin-converting enzyme inhibitor combinations ranked highest for cognitive improvement (SUCRA = 95.3%); however, rankings were highly uncertain due to network sparsity (one study per node).
CONCLUSIONS AND IMPLICATIONS:
Antihypertensive therapy significantly improves cognitive function with moderate certainty evidence, supporting its use for cognitive protection in older adults with hypertension. The trend toward dementia risk reduction, although uncertain, suggests potential long-term benefits warranting further investigation.
CLINICAL IMPLICATIONS:
These findings support optimizing antihypertensive regimens for dementia prevention in high-risk populations, with drug class selection informed by specific treatment goals (dementia prevention vs cognitive maintenance).
POLICY AND RESEARCH IMPLICATIONS:
Current evidence is limited by few studies and short follow-up; large-scale randomized controlled trials with dementia as a primary endpoint, head-to-head drug class comparisons, and inclusion of long-term care residents-who bear the highest disease burden yet are underrepresented in trials-are urgently needed to inform precision prescribing guidelines.
2026-04-01Cureus Journal of Medical Science
Profound Asymptomatic Hyponatremia Associated With Anuric Acute Kidney Injury: Successful Controlled Correction Using Short Intermittent Hemodialysis
Article
作者: El Khand, Ali
Profound hyponatremia (<110 mmol/L) represents a critical electrolyte disturbance associated with significant neurological risk, particularly when rapid correction precipitates osmotic demyelination syndrome. Therapeutic management becomes especially complex when severe hyponatremia coexists with anuric acute kidney injury (AKI) requiring urgent renal replacement therapy, as intermittent hemodialysis may induce abrupt sodium shifts. We describe the case of a 66-year-old hypertensive woman receiving hydrochlorothiazide and perindopril who presented 10 days after cataract surgery with severe anuric AKI, profound asymptomatic hyponatremia (104 mmol/L), hyperkalemia (6.6 mmol/L), elevated creatinine (143 mg/L), and urea (2.6 g/L). Despite the severity of biochemical abnormalities, the patient remained conscious, hemodynamically stable, and neurologically intact, with normal thyroid and adrenal function. Given the urgency of treating hyperkalemia and uremia while avoiding overcorrection of sodium, a carefully individualized intermittent hemodialysis strategy was implemented using ultra-short initial sessions, controlled blood flow (220 mL/min), gradual dialysate sodium adjustment, and concomitant dextrose infusion. This approach enabled progressive correction of serum sodium to 126 mmol/L over four consecutive sessions without exceeding recommended safety thresholds and without neurological complications. This case highlights that meticulously tailored short-duration intermittent hemodialysis can achieve safe sodium correction while addressing life-threatening metabolic indications, suggesting a potential alternative when continuous renal replacement therapy is unavailable.
2026-03-01BIOMEDICINE & PHARMACOTHERAPY
Dual calcium-ACE inhibition reverses non alcoholic fatty pancreas progression: Mechanistic convergence on miR-762/GPX4 driven NLRP3 inflammasome activation
Article
作者: Khaled, Radwa ; Elanwar, Aly ; Attia, Shimaa S ; Saad, Maha ; Hendawy, Nevien ; Yousef, Tarek M ; Shafei, Marwa ; Matboli, Marwa ; Roushdy, Marian Maher Salib ; Hamam, Ghada Galal ; Tolba, Mohamed Ahmed Mohamed ; Mohamed, Nesma Mohamed
BACKGROUND:
Non-alcoholic fatty pancreas (NAFP) is characterized by abnormal pancreatic fat accumulation and remains poorly understood.
AIM:
This study investigates the therapeutic potential and mechanistic basis of low-dose amlodipine-perindopril combination therapy, hypothesizing dual calcium channel blockade and RAS inhibition synergistically disrupt ferroptotic-inflammatory cascades driving pancreatic lipotoxicity.
METHODS:
The bioinformatics analysis of GEO datasets (GSE40901, GSE101462, and GSE194331) identified differentially expressed genes, which were further validated through molecular docking studies with amlodipine and perindoprilat. Male Wistar rats (n = 30) were randomized into five groups: healthy control, NAFP (high-sugar/high-fat diet), amlodipine-treated, perindopril-treated, and combination therapy. Gene expression of GPX4, ACSL4, NLRP3, and rno-miR-762 was quantified by Real-Time PCR. Metabolic parameters, pancreatic histopathology, and immunohistochemical markers (caspase-1, nuclear factor kappa B (NF-κB)) were assessed.
RESULTS:
Bioinformatics analysis revealed significant alterations in ferroptosis and inflammatory pathways. Molecular docking demonstrated favorable binding affinities between therapeutic compounds and target proteins. NAFP induction resulted in GPX4 downregulation (0.471 ± 0.357 vs. 1.197 ± 0.449, P < 0.05), ACSL4 upregulation (48.633 ± 40.998 vs. 1.197 ± 0.445, p < 0.001), elevated NLRP3 (12.717 ± 7.904 vs. 1.115 ± 0.186, p < 0.001), and increased rno-miR-762 expression. The combination therapy achieved 73 % reduction in pancreatic adipocyte area (vs. 42 % with monotherapies, p < 0.001) through coordinated miR-762 suppression (↓68 %, q=0.003) and GPX4 protein restoration (↑2.1-fold, p = 0.008). NLRP3 inflammasome activity decreased by 89 % (p = 0.004). Crucially, the regimen preserved hemodynamic stability, demonstrating metabolic benefits without cardiovascular compromise.
CONCLUSION:
These findings position miR-762 as a linchpin biomarker connecting metabolic stress to ferroptotic pancreatitis, with clinical translation challenges. This work provides the first evidence that sub-therapeutic calcium-RAS crosstalk modulation can reverse established pancreatic steatosis while outlining a precision medicine framework for NAFP prevention.
100 项与 精氨酸培哚普利 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 原发性高血压 | 中国 | 2014-10-17 | |
| 冠状动脉疾病 | 澳大利亚 | 2005-06-08 | |
| 心脏衰竭 | 澳大利亚 | 2005-06-08 | |
| 高血压 | 澳大利亚 | 2005-06-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 224 | (Perindopril) | 鏇蓋選觸廠鑰窪遞網淵(衊襯積構網齋襯蓋夢醖) = 憲鏇餘鏇簾獵製鹹網觸 鏇艱製衊襯獵窪積構顧 (積顧淵餘餘網憲夢夢遞, 0.02) 更多 | - | 2021-01-26 | ||
(Amlodipine) | 鏇蓋選觸廠鑰窪遞網淵(衊襯積構網齋襯蓋夢醖) = 衊簾蓋製鏇醖糧積襯夢 鏇艱製衊襯獵窪積構顧 (積顧淵餘餘網憲夢夢遞, 0.02) 更多 | ||||||
临床4期 | 291 | 襯鹹願選蓋醖膚醖艱蓋 = 遞淵餘觸簾範遞壓網膚 醖範淵構鹽願獵構網選 (築簾壓醖製憲淵窪衊網, 鹹壓範糧鹽鑰築襯繭鑰 ~ 壓簾齋積糧範艱繭鑰壓) 更多 | - | 2017-12-11 | |||
(ACEI Continuation) | 襯鹹願選蓋醖膚醖艱蓋 = 觸醖築顧鬱襯觸襯鹽艱 醖範淵構鹽願獵構網選 (築簾壓醖製憲淵窪衊網, 製鹹繭鬱遞衊鑰醖衊鹽 ~ 鏇選衊醖積簾窪憲醖鑰) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用